PCM
LFCR icon

Prelude Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Prelude Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,004
Closed -$59.5K – 1401
2026
Q1 		$59.5K Sell
16,004
-2,823
-15% -$19.5K ﹤0.01% 1112
2025
Q4 		$154K Buy
+18,827
New +$139K 0.01% 1118
2025
Q3 		– Sell
-13,096
Closed -$106K – 1279
2025
Q2 		$106K Sell
13,096
-10,871
-45% -$73.3K 0.01% 911
2025
Q1 		$169K Buy
23,967
+9,381
+64% +$58.3K 0.01% 977
2024
Q4 		$108K Sell
14,586
-12,918
-47% -$82.5K 0.01% 1088
2024
Q3 		$136K Buy
+27,504
New +$144K 0.01% 1124
2024
Q1 		– Sell
-22,745
Closed -$141K – 1442
2023
Q4 		$141K Buy
+22,745
New +$158K 0.01% 998
2023
Q2 		– Sell
-21,295
Closed -$80.4K – 1253
2023
Q1 		$80.4K Buy
+21,295
New +$119K ﹤0.01% 972
2019
Q4 		– Sell
-1,640
Closed -$18K – 2101
2019
Q3 		$18K Buy
1,640
+951
+138% +$10.4K ﹤0.01% 1408
2019
Q2 		$6K Buy
+689
New +$6.96K ﹤0.01% 1500
2017
Q3 		– Sell
-2,300
Closed -$34K – 1778
2017
Q2 		$34K Buy
+2,300
New +$32K ﹤0.01% 1116
2017
Q1 		– Sell
-400
Closed -$6K – 1638
2016
Q4 		$6K Buy
+400
New +$5.54K ﹤0.01% 1419
2015
Q4 		– Sell
-200
Closed -$2K – 1577
2015
Q3 		$2K Sell
200
-1,400
-88% -$18.5K ﹤0.01% 1432
2015
Q2 		$23K Sell
1,600
-1,300
-45% -$18.8K ﹤0.01% 1325
2015
Q1 		$40K Buy
+2,900
New +$40.1K 0.01% 1434
2014
Q3 		– Sell
-15,300
Closed -$191K – 1996
2014
Q2 		$191K Buy
15,300
+900
+6% +$10.6K 0.03% 762
2014
Q1 		$161K Sell
14,400
-5,614
-28% -$61.6K 0.02% 810
2013
Q4 		$243K Buy
20,014
+754
+4% +$9K 0.04% 569
2013
Q3 		$235K Buy
+19,260
New +$269K 0.04% 491

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Prelude Capital Management's LFCR Position: Q2 2026 in Review

Prelude Capital Management sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 16,004 shares — an estimated $59.5K sold.

Prelude Capital Management first reported a position in LFCR in Q3 2013 and held it in 19 quarters. The position peaked at $243K in Q4 2013. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Prelude Capital Management reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 16,004 Lifecore Biomedical shares in Q2 2026, an estimated $59.5K.
  • Prelude Capital Management first reported a position in Lifecore Biomedical in Q3 2013 and held it in 19 quarters.
  • Prelude Capital Management's Lifecore Biomedical position peaked at $243K in Q4 2013.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.